Frazier Life Sciences Management,
$4.6B 13F equity value
44 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Frazier Life Sciences Management, covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| MIRM | MIRUM PHARMACEUTICALS INC | 7,679,684 | $899M | 19.6% |
| NAMS | NEWAMSTERDAM PHARMA COMPANY | 18,088,902 | $613M | 13.3% |
| ERAS | ERASCA INC | 24,975,188 | $458M | 10.0% |
| MBX | MBX BIOSCIENCES INC | 6,652,013 | $367M | 8.0% |
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | 9,874,511 | $259M | 5.6% |
| TRVI | TREVI THERAPEUTICS INC | 9,939,447 | $185M | 4.0% |
| KRYS | KRYSTAL BIOTECH INC | 481,307 | $179M | 3.9% |
| MAZE | MAZE THERAPEUTICS INC | 5,032,915 | $150M | 3.3% |
| PHAT | PHATHOM PHARMACEUTICALS INC | 12,466,489 | $135M | 2.9% |
| PVLA | PALVELLA THERAPEUTICS INC NE | 882,400 | $135M | 2.9% |
Track Frazier Life Sciences Management,'s 13F portfolio: $4.6B in reported holdings, 44 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}